• 1
    Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220226.
  • 2
    Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: BloomFE, KupferDJ, editors. Psychopharmacology: The fourth generation of progress. New York : Raven Press, 1995;933944.
  • 3
    Heninger GR, Charney DS. Mechanisms of action of antidepressant treatments: Implications for the ethiology and treatment of depression disorders. In: MeltzerHY, editor. Psychopharmacology: The third generation of progress. New York : Raven Press, 1987;535544.
  • 4
    Delgado PL. Monoamine depletion studies: Implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67(Suppl 4):2226.
  • 5
    Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psych 2007;64:327337.
  • 6
    Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965;122:509522.
  • 7
    Bunney WE Jr., Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 1965;13:483494.
  • 8
    Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117128.
  • 9
    Roiser JP, McLean A, Ogilvie AD, et al. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology 2005;30:775785.
  • 10
    Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:117.
  • 11
    Ordawy GA, Mann JJ. Neurocircuitry of mood disorders. In: DavisKL, CoyleJT, NemeroffC, editors. Neuropsychopharmacology: The fifth Generation of Progress. Philadelphia : Lippinkott Williams & Willkins, 2002;10511064.
  • 12
    Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):3040.
  • 13
    Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008;69:246258.
  • 14
    Swanson LW. The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 1982;9:321353.
  • 15
    Geffard M, Buijs RM, Seguela P, Pool CW, Le Moal M. First demonstration of highly specific and sensitive antibodies against dopamine. Brain Res 1984;294:161165.
  • 16
    Bouthenet ML, Martres MP, Sales N, Schwartz JC. A detailed mapping of dopamine D2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride. Neuroscience 1987;20:117155.
  • 17
    Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 1991;564:203219.
  • 18
    Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 1998;779:5874.
  • 19
    Yokoyama C, Okamura H, Nakajima T, Taguchi J, Ibata Y. Autoradiographic distribution of [3H]YM-09151–2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol 1994;344:121136.
  • 20
    Ornstein K, Milon H, McRae-Degueurce A, Alvarez C, Berger B, Wurzner HP. Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J Neural Transm 1987;70:183191.
  • 21
    Guiard BP, El Mansari M, Blier P. Crosstalk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus coeruleus, and dorsal hippocampus. Mol Pharmacol 2008;74:14631475.
  • 22
    Elam M, Clark D, Svensson TH. Electrophysiological effects of the enantiomers of 3-PPP on neurons in the locus coeruleus of the rat. Neuropharmacology 1986;25:10031008.
  • 23
    Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization. Eur J Pharmacol 1977;44:375385.
  • 24
    Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: An in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008;11:625639.
  • 25
    Piercey MF, Smith MW, Lum-Ragan JT. Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther 1994;268:12971303.
  • 26
    Nilsson LK, Schwieler L, Engberg G, Linderholm KR, Erhardt S. Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: Involvement of glutamatergic mechanisms. Int J Neuropsychopharmacol 2005;8:329339.
  • 27
    Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009;34:651661.
  • 28
    El Mansari M, Ghanbari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008;55:11911198.
  • 29
    Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001;155:5257.
  • 30
    Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994;11:133141.
  • 31
    Crochet S, Sakai K. Dopaminergic modulation of behavioral states in mesopontine tegmentum: A reverse microdialysis study in freely moving cats. Sleep 2003;26:801806.
  • 32
    Jones BE, Halaris AE, McIlhany M, Moore RY. Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res 1977;127:121.
  • 33
    Phillipson OT. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxidase study in the rat. J Comp Neurol 1979;187:117143.
  • 34
    Simon H, Le Moal M, Stinus L, Calas A. Anatomical relationships between the ventral mesencephalic tegmentum – A 10 region and the locus coeruleus as demonstrated by anterograde and retrograde tracing techniques. J Neural Transm 1979;44:7786.
  • 35
    Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 2000;420:211232.
  • 36
    Geisler S, Zahm DS. Afferents of the ventral tegmental area in the rat-anatomical substratum for integrative functions. J Comp Neurol 2005;490:270294.
  • 37
    Mejías-Aponte CA, Drouin C, Aston-Jones G. Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: Prominent inputs from medullary homeostatic centers. J Neurosci 2009;29:36133626.
  • 38
    Liprando LA, Miner LH, Blakely RD, Lewis DA, Sesack SR. Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Synapse 2004;52:233244.
  • 39
    Jones LS, Gauger LL, Davis JN. Anatomy of brain alpha 1-adrenergic receptors: In vitro autoradiography with [125I]-heat. J Comp Neurol 1985;231:190208.
  • 40
    Lee A, Wissekerke AE, Rosin DL, Lynch KR. Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience 1998;84:10851096.
  • 41
    Reith ME, Li MY, Yan QS. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl). 1997;134:309317.
  • 42
    Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001;297:540546.
  • 43
    Shi WX, Pun CL, Smith PL, Bunney BS. Endogenous DA-mediated feedback inhibition of DA neurons: Involvement of both D(1)- and D(2)-like receptors. Synapse 2000;35:111119.
  • 44
    Grenhoff J, Svensson TH. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol 1993;233:7984.
  • 45
    Grenhoff J, Svensson TH. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur J Pharmacol 1989;165:1118.
  • 46
    White FJ, Wang RY. Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: Microiontophoretic studies. J Pharmacol Exp Ther 1984;231:275280.
  • 47
    Aghajanian GK, Bunney BS. Pharmacological characterization of dopamine “autoreceptors” by microiontophoretic single-cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 1977;297:17.
  • 48
    Aghajanian GK, Bunney BS. Pharmacological characterization of dopamine “autoreceptors” by microiontophoretic single-cell recording studies. Adv Biochem Psychopharmacol 1977;16:433438.
  • 49
    White FJ, Wang RY. A10 dopamine neurons: Role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci 1984;34:11611170.
  • 50
    Gobbi G, Muntoni AL, Gessa GL, Diana M. Clonidine fails to modify dopaminergic neuronal activity during morphine withdrawal. Psychopharmacology (Berl) 2001;158:16.
  • 51
    Georges F, Aston-Jones G. Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: Participation of imidazoline and norepinephrine receptors. Neuropsychopharmacology 2003;28:11401149.
  • 52
    Katz N, Guiard BP, El Mansari M, Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol 2009; [Epub ahead of print]. doi:10.1177/0269881109348178.
  • 53
    Aman TK, Shen RY, Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther 2007;320:376385.
  • 54
    Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors. Curr Drug Targets 2009;10:10691084.
  • 55
    Page M, Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 2002;27:237247.
  • 56
    Baumann, MH, Char GU, De Costa BR, Rice KC, Rothman RB. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 1994;271:12161222.
  • 57
    Guiard B, Chenu F, El Mansari M, Blier P. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychopharmacol, in press. doi:10.1017/S1461145710000076.
  • 58
    Carboni E, Silvagni A. Dopamine reuptake by norepinephrine neurons: Exception or rule? Crit Rev Neurobiol 2004;16:121128.
  • 59
    Devoto P, Flore G. On the origin of cortical dopamine: Is it a co-transmitter in noradrenergic neurons? Curr Neuropharmacol 2006;4:115125.
  • 60
    Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990;55:10671070.
  • 61
    Di Chiara G, Tanda GL, Frau R, Carboni E. Heterologous monoamine reuptake: Lack of transmitter specificity of neuron-specific carriers. Neurochem Int 1992;20:231S235S.
  • 62
    Tanda G, Carboni E, Frau R, Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology (Berl) 1994;115:285288.
  • 63
    Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998;71:274280.
  • 64
    Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994;269:1598515988.
  • 65
    Gu H, Wall SC, Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 1994;269:71247130.
  • 66
    Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 1994;63:195200.
  • 67
    Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci 2002;22:389395.
  • 68
    Kawahara H, Kawahara Y, Westerink BH. The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. Eur J Pharmacol 2001;27;418:177186.
  • 69
    Devoto P, Flore G, Saba P, et al. 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. J Neurosci Res 2008;86:16471658.
  • 70
    Goldman-Rakic PS. Cellular and circuit basis of working memory in prefrontal cortex of nonhuman primates. Prog Brain Res 1990;85:325335.
  • 71
    Goldman-Rakic PS. Cellular basis of working memory. Neuron 1995;14:477485.
  • 72
    Clark L, Chamberlain SR, Sahakian BJ. Neurocognitive mechanisms in depression: Implications for treatment. Annu Rev Neurosci 2009;32:5774.
  • 73
    Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929932.
  • 74
    Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129:397410.
  • 75
    Seamans JK, Floresco SB, Phillips AG. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J Neurosci 1998;18:16131621.
  • 76
    Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007;10:376384.
  • 77
    Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 2009;23(Suppl 1):3341.
  • 78
    Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: A rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007;17(Suppl 1):i615.
  • 79
    Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;10:410422.
  • 80
    Yang CR, Seamans JK. Dopamine D1 receptor actions in layers V-VI rat prefrontal cortex neurons in vitro: Modulation of dendritic-somatic signal integration. J Neurosci 1996;16:19221935.
  • 81
    Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006;50:755760.
  • 82
    Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:11111120.
  • 83
    Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 2005;1:29.
  • 84
    Biederman J, Arnsten AF, Faraone SV, et al. New developments in the treatment of ADHD. J Clin Psychiatry 2006;67:148159.
  • 85
    Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation. Annu Rev Neurosci 2009;32:267287.
  • 86
    Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(Suppl 3):S7S14.
  • 87
    Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:5865.
  • 88
    Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disord 2002;4:307314.
  • 89
    Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999;156:798803.
  • 90
    Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: An open case series. Pharmacopsychiatry 2001;34:137141.
  • 91
    Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in treatment of unipolar and bipolar depression: A retrospective chart review. Ann Clin Psychiatry 2000;12:137140.
  • 92
    DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 2000;20:274275.
  • 93
    Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. Pramipexole in treatment-resistant depression: An extended follow-up. Depress Anxiety 2004;20:131138.
  • 94
    Carter AJ, Müller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:6572.
  • 95
    Pitts DK, Wang L, Kelland MD, Freeman AS, Chiodo LA. Repeated stimulation of dopamine D2-like receptors: Reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole. J Pharmacol Exp Ther 1995;275:412421.
  • 96
    Chernoloz O, El Mansari M, Blier P. Effects of pramipexole administration on monoaminergic neurotransmission. European Neuropsychopharmacol 2009;19(Suppl 1):S8.
  • 97
    Gillings D, Grizzle J, Koch G, et al. Pooling 12 nomifensine studies for efficacy generalizability. J Clin Psychiatry 1984;45:7884.
  • 98
    Bremner JD, Abrahams LM, Crupie JE, McCawley A, Proctor RC, Sathananthan GL. Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. J Clin Psychiatry 1984;45:5659.
  • 99
    Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001;13:20772087.
  • 100
    Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002;302:983991.
  • 101
    Hatanaka K, Yatsugi S, Yamaguchi T. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol 2000;395:3136.
  • 102
    Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355363.
  • 103
    Martin-Ruiz R, Ugedo L, Honrubia MA, Mengod G, Artigas F. Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J Neurochem 2001;77:762775.
  • 104
    Mongeau R, Blier P, De Montigny C. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev 1997;23:145195.
  • 105
    Szabo ST, Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001;25:845857.
  • 106
    Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 2007;194:6372.
  • 107
    Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl) 2009;206:335344.
  • 108
    Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006;59:203210.
  • 109
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:12431252.
  • 110
    Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395401.
  • 111
    Ferris RM, Beaman OJ. Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 1983;22:12571267.
  • 112
    Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Reviews 2006;12:178207.
  • 113
    Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002;163:102105.
  • 114
    Learned-Coughlin SM, Bergstorm M, Savitcheva I, Ascher J, Schmith VD, Langstorm B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54:800805.
  • 115
    Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003;28:413420.
  • 116
    Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, Pavics L. Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005;89:115123.
  • 117
    Gobbi G, Slater S, Boucher N, Debonnel G, Blier P. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol 2003;23:233239.
  • 118
    Baraban JM, Wang RY, Aghajanian G. Reserpine suppression of dorsal raphe neuronal firing: Mediation by adrenergic system. Eur J Pharmacol 1978;52:2736.
  • 119
    Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 1975;92:291306.
  • 120
    Blier P, De Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: Electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1986;237:987994.
  • 121
    Ghanbari R, El Mansari M, Blier P. Electrophysiological effects of sustained administration of bupropion on serotonergic and noradrenergic neurotransmission in the rat hippocampus. Biol Psychiatry 2009;65(8S):545.
  • 122
    Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992;7:714.
  • 123
    Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002;42:181190.
  • 124
    Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol 2003;95:652656.
  • 125
    Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 1990;6:106112.
  • 126
    Stamford JA, Kruk ZL, Millar J. Dissociation of the actions of uptake blockers upon dopamine overflow and uptake in the rat nucleus accumbens: In vivo voltammetric data. Neuropharmacology 1989;28:13831388.
  • 127
    Caruana DA, Sorge RE Stewart J, Chapman CA. Dopamine has bidirectional effects on synaptic responses to cortical inputs in layer II of the lateral entorhinal cortex. J Neurophysiol 2006;96:30063015.
  • 128
    Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:5773.
  • 129
    Calabrese JR. Efficacy of quetiapine monothreapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600609.
  • 130
    Thase ME, Macfadden W, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I and II depression. Am J Psychiatry 2005;162:13511360.
  • 131
    Young A, McElroy S, Chang W, Olausson B, Paulsson B, Brecher M, Nordenhem A. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Int J Neuropsychopharmacol 2008;11(Suppl 1):S186.
  • 132
    Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: A comparison with citalopram. Eur J Neurosci 2000;12:10791095.
  • 133
    Haddjeri N, Blier P, De Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998;51:255266.
  • 134
    Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopaime release in the rat prefrontal cortex. Eur J Pharmacol 2004;504:6164.
  • 135
    Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:12891297.
  • 136
    Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004;55:11031109.
  • 137
    Seager MA, Barth VN, Phebus LA, Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: Implications for bipolar disorder. Psychopharmacology (Berl) 2005;181:126133.
  • 138
    Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: Electrophysiologic studies in the rat brain. Biol Psychiatry 2007;61:671678.
  • 139
    Jensen NH, Rodriguez RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:23032312.
  • 140
    Dennis T, L’Heureux R, Carter C, Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 1987;241:642649.
  • 141
    Blier P, Ward P, Trembley P, Laberge L, Hebert C, Bergeron  . Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. Am J Psychiatry 2010;167:281288.
  • 142
    Papakostas GI, Worthington JJ 3rd., Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006;23:178181.
  • 143
    Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197206.
  • 144
    Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: A randomized trial. Ann Intern Med 2007;147:593602.
  • 145
    Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205214.